| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sabrina Wong, Angela T H Kwan, Kayla M Teopiz, Gia Han Le, Shakila Meshkat, Roger Ho, Giacomo d'Andrea, Bing Cao, Joshua D Di Vincenzo, Joshua D Rosenblat, Roger S McIntyr. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Journal of affective disorders. 2024-01-20. PMID:38244804. |
esketamine is a proven treatment recently approved for adults with treatment-resistant depression (trd) while psilocybin is an investigational treatment. |
2024-01-20 |
2024-01-23 |
Not clear |
| Fatima Iftikhar Shah, Somia Shehzadi, Fatima Akram, Ikram Ul Haq, Benish Javed, Sadeed Sabir, Yasha Kazim, Sehrish Ashfa. Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy. Molecular biotechnology. 2023-12-20. PMID:38117395. |
this comprehensive review explores psilocybin, derived from specific mushrooms, and its implications in the treatment of depression. |
2023-12-20 |
2023-12-23 |
Not clear |
| Nicholas Kolbman, Tiecheng Liu, Peter Guzzo, Jim Gilligan, George A Mashour, Giancarlo Vanini, Dinesh Pa. Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain. Current biology : CB. vol 33. issue 24. 2023-12-19. PMID:38113836. |
in particular, psilocybin has shown promise for the treatment of refractory depression |
2023-12-19 |
2023-12-23 |
rat |
| Scott T Aaronson, Andrew van der Vaart, Tammy Miller, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Harold A Sackeim, Trisha Suppe. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial. JAMA psychiatry. 2023-12-06. PMID:38055270. |
psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression. |
2023-12-06 |
2023-12-10 |
Not clear |
| James J Gattuso, Carey Wilson, Anthony J Hannan, Thibault Renoi. Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review. Journal of neurochemistry. 2023-11-29. PMID:38019032. |
psilocybin has begun to show efficacy for a range of neuropsychiatric conditions, including treatment-resistant depression and anxiety disorders; however, neurobiological mechanisms are still being elucidated. |
2023-11-29 |
2023-12-07 |
human |
| James J Gattuso, Carey Wilson, Anthony J Hannan, Thibault Renoi. Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review. Journal of neurochemistry. 2023-11-29. PMID:38019032. |
we found that psilocybin shows promise as a lead candidate molecule for treating a variety of neuropsychiatric conditions, albeit showing the most efficacy for depression. |
2023-11-29 |
2023-12-07 |
human |
| Huda Ahmed, Hasan Mushahid, Talal Arsha. UNCOVERING THE UNTAPPED POTENTIAL OF PSILOCYBIN THERAPY IN ALLEVIATING CANCER-RELATED DEPRESSION: AN URGENT CALL TO RE-EVALUATE TREATMENT STRATEGIES. Psychiatria Danubina. vol 35. issue 4. 2023-11-24. PMID:37992112. |
uncovering the untapped potential of psilocybin therapy in alleviating cancer-related depression: an urgent call to re-evaluate treatment strategies. |
2023-11-24 |
2023-11-28 |
Not clear |
| Elizabeth Boudreau, Krissa Orlowsk. Psilocybin therapy to reduce depression following a terminal diagnosis. JAAPA : official journal of the American Academy of Physician Assistants. vol 36. issue 12. 2023-11-21. PMID:37989175. |
psilocybin therapy to reduce depression following a terminal diagnosis. |
2023-11-21 |
2023-11-29 |
Not clear |
| Sheetal A Raithatha, Jillian M Hagel, Kaveh Matinkhoo, Lisa Yu, David Press, Sarah G Cook, Govinda Sharma, D Dhananjaya, Glynnis Jensen, Jessica B Lee, Charlie Cai, Jonathan Gallant, Jaideep Bains, Joseph E Tucker, Peter J Facchin. Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders. Journal of medicinal chemistry. 2023-11-20. PMID:37983270. |
despite positive clinical end points targeting depression and anxiety, concerns regarding the duration of the psychedelic experience produced by psilocybin, associated with enduring systemic exposure to the active metabolite psilocin, pose a barrier to its therapeutic application. |
2023-11-20 |
2023-11-29 |
Not clear |
| Anees Bahji, Isis Lunsky, Gilmar Gutierrez, Gustavo Vazque. Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. Journal of psychoactive drugs. 2023-11-16. PMID:37968944. |
eighteen studies were identified, which suggested that psychedelic therapies were well tolerated and presented a large effect size for the management of depression symptoms in a transdiagnostic population with psilocybin (g = -1.92, 95% ci, -2.73 to -1.11) and mdma (g = -0.71; 95% ci, -1.39 to -0.03). |
2023-11-16 |
2023-11-20 |
Not clear |
| D J Nutt, J M Peill, B Weiss, K Godfrey, R L Carhart-Harris, D Erritzo. Psilocybin and Other Classic Psychedelics in Depression. Current topics in behavioral neurosciences. 2023-11-13. PMID:37955822. |
psilocybin and other classic psychedelics in depression. |
2023-11-13 |
2023-11-20 |
Not clear |
| D J Nutt, J M Peill, B Weiss, K Godfrey, R L Carhart-Harris, D Erritzo. Psilocybin and Other Classic Psychedelics in Depression. Current topics in behavioral neurosciences. 2023-11-13. PMID:37955822. |
psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatment of depression. |
2023-11-13 |
2023-11-20 |
Not clear |
| Uriel Heresco-Levy, Bernard Lere. Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. Molecular psychiatry. 2023-11-09. PMID:37945694. |
we propose to initially focus research on the acute concurrent administration of psilocybin and dsr or dcs in depression. |
2023-11-09 |
2023-11-20 |
Not clear |
| Zofia Kozak, Matthew W Johnson, Scott T Aaronso. Assessing potential of psilocybin for depressive disorders. Expert opinion on investigational drugs. 2023-11-02. PMID:37869790. |
several clinical trials have shown psilocybin to have efficacy in reducing symptoms of depression. |
2023-11-02 |
2023-11-08 |
Not clear |
| Arya Rahbarnia, Zhaoxia Li, Paul J Fletche. Effects of psilocybin, the 5-HT Psychopharmacology. 2023-10-19. PMID:37855864. |
effects of psilocybin, the 5-ht neuropsychiatric disorders such as depression are characterized in part by attention deficits. |
2023-10-19 |
2023-11-08 |
Not clear |
| Sipan Haikazian, David C J Chen-Li, Danica E Johnson, Farhan Fancy, Anastasia Levinta, M Ishrat Husain, Rodrigo B Mansur, Roger S McIntyre, Joshua D Rosenbla. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry research. vol 329. 2023-10-16. PMID:37844352. |
systematic searches were conducted to search for randomized clinical trials and open-label trials that evaluated depression symptoms after psilocybin therapy. |
2023-10-16 |
2023-11-08 |
Not clear |
| Sipan Haikazian, David C J Chen-Li, Danica E Johnson, Farhan Fancy, Anastasia Levinta, M Ishrat Husain, Rodrigo B Mansur, Roger S McIntyre, Joshua D Rosenbla. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry research. vol 329. 2023-10-16. PMID:37844352. |
the primary outcome was the standardized mean difference (smd) in depression severity, determined by calculating the change in depression ratings from baseline to the primary endpoint in the psilocybin arm versus the control arm. |
2023-10-16 |
2023-11-08 |
Not clear |
| Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek, Andrzej Pil. Potential use of psilocybin drugs in the treatment of depression. Expert opinion on emerging drugs. 2023-10-11. PMID:37817501. |
potential use of psilocybin drugs in the treatment of depression. |
2023-10-11 |
2023-10-15 |
Not clear |
| Kwonmok Ko, Ben Carter, Anthony J Cleare, James J Rucke. Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis. Neuropsychiatric disease and treatment. vol 19. 2023-10-11. PMID:37818448. |
determining predictors of their intensity is, therefore, potentially beneficial in targeting psilocybin therapy for depression. |
2023-10-11 |
2023-10-15 |
Not clear |
| Haniya J Halim, Bradley G Burk, Rachel E Fargason, Badari Biru. Manic episode following psilocybin use in a man with bipolar II disorder: a case report. Frontiers in psychiatry. vol 14. 2023-10-09. PMID:37810598. |
psilocybin is a psychedelic drug that has recently garnered increased interest as an effective treatment modality for treatment-resistant depression, depression associated with terminal conditions, certain substance use disorders, and obsessive-compulsive disorder. |
2023-10-09 |
2023-10-15 |
Not clear |